Omalizumab,as a biological agent targeting IgE,is a recombinant humanized monoclonal antibody and the first targeted drug approved for treating moderate-to-severe bronchial asthma.By reviewing one case of aspirin-induced asthma complicated with nasosinusitis and otitis media,we discussed the value of omalizumab in the treatment of asthma and its complications,aiming to provide a reference for clinical practice.
奥马珠单抗是一种重组人源化单克隆抗体,为抗IgE靶向生物制剂,是全球首个获批治疗中至重度支气管哮喘的靶向治疗药物。本文对1例阿司匹林哮喘伴分泌性中耳炎及鼻窦炎患者进行回顾性分析,探讨奥马珠单抗在治疗哮喘及其合并症中的价值,为临床实践提供依据。.
Keywords: asthma; nasosinusitis; omalizumab; otitis media.